Immuneering Q2 net loss $11.5M; IND for IMM-1-104 on track this quarter

Immuneering Corp

2022-Q2 EPS reported -$0.93 revenue$278,117

Net loss of $11.5M ($0.44 per share) vs $8.0M ($1.61) in Q2 2021.
Cash and marketable securities $128.1M as of June 30, 2022, down from $150.2M at Dec 31, 2021.
Management reiterates FY 2022 GAAP operating expense guidance of $55M-$60M.
IND filing for IMM-1-104 (pan-KRAS/NRAS) expected this quarter; first patient enrollment expected Q4 2022.
IND application for IMM-6-415 (MEK-IO program) expected in 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.